These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35658835)

  • 21. Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.
    Hsieh E; Fraenkel L; Xia W; Hu YY; Han Y; Insogna K; Yin MT; Xie J; Zhu T; Li T
    Osteoporos Int; 2015 Mar; 26(3):1035-44. PubMed ID: 25224293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study.
    Namme Luma H; Doualla MS; Choukem SP; Temfack E; Ashuntantang G; Achu Joko H; Koulla-Shiro S
    Pan Afr Med J; 2012; 12():87. PubMed ID: 23077708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of liver and renal functions in human immunodeficiency virus-infected persons on highly active antiretroviral therapy: A mixed cohort study.
    Mahajan VK; Wadhwa D; Sharma A; Chauhan S; Vashist S; Kumar P; Chowdhry B
    Indian J Dermatol Venereol Leprol; 2020; 86(5):499-507. PubMed ID: 31975695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
    Kumarasamy N; Venkatesh KK; Cecelia AJ; Devaleenal B; Lai AR; Saghayam S; Balakrishnan P; Yepthomi T; Poongulali S; Flanigan TP; Solomon S; Mayer KH
    AIDS Patient Care STDS; 2008 Apr; 22(4):337-44. PubMed ID: 18422462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
    Yu XD; Huang H; Jiao Y; Li J; Fan X; Zhang D; Wang FS
    Lipids Health Dis; 2023 Feb; 22(1):27. PubMed ID: 36823632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of first-line combination antiretroviral therapy with malaria among adult HIV-infected persons in Jos, Nigeria: a pilot cross sectional study.
    Onukak A; Aninagyei E; Ekuma A; Gomerep S; Shehu N; Isa S
    BMC Infect Dis; 2024 Sep; 24(1):1038. PubMed ID: 39333924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs.
    Ombeni W; Kamuhabwa AR
    J Int Assoc Provid AIDS Care; 2016; 15(2):164-71. PubMed ID: 26514630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
    Sreenivasan S; Dasegowda V
    J Infect Dev Ctries; 2010 Nov; 4(11):750-3. PubMed ID: 21252454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
    Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C;
    Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
    Zijenah LS; Kadzirange G; Rusakaniko S; Kufa T; Gonah N; Tobaiwa O; Gwanzura C; Matsikire E; Katzenstein DA
    Cent Afr J Med; 2006; 52(1-2):1-8. PubMed ID: 17892232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine-Induced Skin Rash Remains an Underdiagnosed Entity in HIV: A Case Series from a Single Center.
    Sachdeva RK; Sharma A; De D; Malhi J; Rewari BB; Singh S; Varma S
    J Int Assoc Provid AIDS Care; 2016; 15(2):153-8. PubMed ID: 26310925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.